Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

1. Teriparatide (Osnuvo) - osteoporosis

Teriparatide (Osnuvo) - osteoporosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

2. Denosumab (Prolia) and steroid-induced osteoporosis

Denosumab (Prolia) and steroid-induced osteoporosis Prescrire IN ENGLISH - Spotlight ''Denosumab (Prolia°) and steroid-induced osteoporosis'', 1 April 2020 {1} {1} {1} | | > > > Denosumab (Prolia°) and steroid-induced osteoporosis Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the April issue of Prescrire International: Denosumab (Prolia (...) °) and steroid-induced osteoporosis FREE DOWNLOAD Denosumab (Prolia°) has an unfavourable harm-benefit balance in the prevention of osteoporotic fractures. It has also been authorised in the prevention of osteoporosis induced by prolonged corticosteroid therapy. How do Prescrire's editors rate denosumab in this situation? Full text available for free download. Prescrire's rating NOT ACCEPTABLE Denosumab has not been shown to prevent clinical fractures, but it has many adverse effects that can be severe

2020 Prescrire

3. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Full Text available with Trip Pro

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Navbar Search Filter Mobile (...) Microsite Search Term search filter search input Article Navigation Close mobile search navigation Article Navigation March 2020 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Dolores Shoback Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, Department of Medicine , San Francisco, California Department of Medicine, University of California San Francisco , San Francisco, California Search

2020 The Endocrine Society

4. Romosozumab (Evenity) - treatment of osteoporosis in postmenopausal women at high risk for fracture

Romosozumab (Evenity) - treatment of osteoporosis in postmenopausal women at high risk for fracture Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study (Abstract)

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining bone formation. Previous work has shown that odanacatib increases bone mineral density in postmenopausal women with low bone mass. We aimed to investigate the efficacy and safety of odanacatib to reduce fracture risk in postmenopausal women (...) , more than one vertebral fracture, or a T-score of less than -4·0 at the total hip or femoral neck were not eligible unless they were unable or unwilling to use approved osteoporosis treatment. Participants were randomly assigned (1:1) to either oral odanacatib (50 mg once per week) or matching placebo. Randomisation was done using an interactive voice recognition system after stratification for previous radiographic vertebral fracture, and treatment was masked to study participants, investigators

2019 EvidenceUpdates

6. Romosozymab (Evenity) - Osteoporosis

Romosozymab (Evenity) - Osteoporosis Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing

2019 Health Canada - drugs and medical devices

7. Diagnosis of osteoporosis in statin-treated patients is dose-dependent Full Text available with Trip Pro

Diagnosis of osteoporosis in statin-treated patients is dose-dependent Whether HMG-CoA-reductase inhibition, the main mechanism of statins, plays a role in the pathogenesis of osteoporosis, is not entirely known so far. Consequently, this study was set out to investigate the relationship of different kinds and dosages of statins with osteoporosis, hypothesising that the inhibition of the synthesis of cholesterol could influence sex-hormones and therefore the diagnosis of osteoporosis.Medical (...) claims data of all Austrians from 2006 to 2007 was used to identify all patients treated with statins to compute their daily defined dose averages of six different types of statins. We applied multiple logistic regression to analyse the dose-dependent risks of being diagnosed with osteoporosis for each statin individually.In the general study population, statin treatment was associated with an overrepresentation of diagnosed osteoporosis compared with controls (OR: 3.62, 95% CI 3.55 to 3.69, p<0.01

2019 EvidenceUpdates

8. Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines

Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines | CADTH.ca Find the information you need Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Last updated: August 22, 2019 Project Number (...) : RA1059-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical evidence for varying treatment duration and courses of bisphosphonates for osteoporosis? What are the evidence-based guidelines regarding length of treatment with bisphosphonates for osteoporosis? Key Message One health technology assessment, six systematic reviews (one with meta-analyses), three randomized controlled trials, and five non-randomized studies were identified

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women

Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women | CADTH.ca Find the information you need Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Last updated: October 11, 2019 Project Number: HE0023-000 Product Line: Technology Review Research Type: Drug Result type: Report Expected (...) Completion Date: December 20, 2019 Osteoporosis is a systemic skeletal disease characterized by a loss of bone mass and an increased risk of fragility fractures. Osteoporosis is highly prevalent, affecting an estimated 1.5 million Canadians over 40 years of age. Fractures associated with osteoporosis commonly occur in vertebral sites, but also occur in non-vertebral sites. They are associated with significant costs, diminished quality of life, and mortality, as well as an increased risk of future

2019 CADTH - Technology Review

10. Pharmacological Management of Osteoporosis in Postmenopausal Women Full Text available with Trip Pro

Pharmacological Management of Osteoporosis in Postmenopausal Women We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation May 2019 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline Richard Eastell University of Sheffield, Sheffield, United Kingdom Search for other works by this author on: Clifford J Rosen Maine Medical Center Research Institute, Scarborough, Maine Correspondence: Clifford J. Rosen, MD

2019 The Endocrine Society

11. What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it?

What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism

2019 Clinical Correlations

12. Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture

Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture Drug Approval Package: Evenity U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Evenity Company: Amgen Inc. Application Number: 761062 Approval Date: 04/09/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2019 FDA - Drug Approval Package

13. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 (...) . Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19-EHC016-EF April 2019 ii Key Messages Purpose of Review To summarize the effects of long-term osteoporosis drug treatment and of osteoporosis drug treatment discontinuation and holidays. Key Messages • Evidence on the effects of long-term osteoporosis drug treatment and drug continuation versus discontinuation is mostly limited to white, healthy, postmenopausal women. • Long-term alendronate reduces radiographic vertebral and nonvertebral fractures

2019 Effective Health Care Program (AHRQ)

14. Osteoporosis. (Abstract)

Osteoporosis. Fractures resulting from osteoporosis become increasingly common in women after age 55 years and men after age 65 years, resulting in substantial bone-associated morbidities, and increased mortality and health-care costs. Research advances have led to a more accurate assessment of fracture risk and have increased the range of therapeutic options available to prevent fractures. Fracture risk algorithms that combine clinical risk factors and bone mineral density are now widely used (...) in clinical practice to target high-risk individuals for treatment. The discovery of key pathways regulating bone resorption and formation has identified new approaches to treatment with distinctive mechanisms of action. Osteoporosis is a chronic condition and long-term, sometimes lifelong, management is required. In individuals at high risk of fracture, the benefit versus risk profile is likely to be favourable for up to 10 years of treatment with bisphosphonates or denosumab. In people at a very high

2019 Lancet

15. The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper Full Text available with Trip Pro

The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper - Hill - - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term (...) The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free Access The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper Department of Haematology, Leeds Teaching Hospitals, Leeds, UK Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK Faculty

2019 British Committee for Standards in Haematology

16. Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. Full Text available with Trip Pro

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. This study evaluated the effects of combination therapy of curcumin and alendronate on BMD and bone turnover markers in postmenopausal women with osteoporosis.In a randomized, double-blind trial study, 60 postmenopausal women were divided into three groups: control, alendronate, and alendronate + curcumin. Each group included 20 patients (...) also increased in four areas significantly at the end of study compared to the control and alendronate groups.The combination of curcumin and alendronate has beneficial effects on BMD and bone turnover markers among postmenopausal women with osteoporosis. Arch Endocrinol Metab. 2018;62(4):438-45.

2018 Archives of endocrinology and metabolism Controlled trial quality: uncertain

17. Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia Full Text available with Trip Pro

Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia To examine the effect of 25-hydroxyvitamin D (25(OH)D) levels recommended by Endocrine Society guidelines (>30 ng/mL) on cognition in healthy older African-American women over 3 years.Randomized, double-blind, placebo-controlled clinical trial.Bone Mineral Research Center at New York University Winthrop Hospital.Healthy

2018 EvidenceUpdates

18. Denosumab (Prolia) and osteoporosis: an increasingly unfavourable harm-benefit balance

Denosumab (Prolia) and osteoporosis: an increasingly unfavourable harm-benefit balance Prescrire IN ENGLISH - Spotlight ''Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance '', 1 November 2018 {1} {1} {1} | | > > > Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance Reports of sometimes serious adverse effects tilt the harm-benefit balance of denosumab in the treatment of osteoporosis. Denosumab is authorised in some cases of osteoporosis and bone metastases. As expected from the pre-market evaluation of denosumab, reports of adverse reactions related to disruption of the immune system attributed to denosumab are accumulating. To date

2018 Prescrire

19. Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study (Abstract)

Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study To evaluate the association between cataract and cataract surgery and risks of osteoporosis and fracture.Nationwide population-based retrospective cohort study.Taiwan's National Health Insurance Research Database.Individuals with (n=57,972) and without (n=57,972) cataracts.Individuals with and without cataracts were matched 1:1 for age, sex, and index year. Those with cataracts were further divided (...) into cataract surgery and nonsurgery groups. Incidences and hazard ratios (HR) for risks of developing osteoporosis and fracture were calculated using Cox proportional hazard regression models.During mean follow-up of 6.4 years, 17,450 participants with cataracts and 12,627 without developed osteoporosis or fractures. Having cataracts was significantly associated with risk of developing osteoporosis or fracture (adjusted HR (aHR) = 1.29, 95% confidence interval (CI) = 1.25-1.32, p < .001). In analyses

2018 EvidenceUpdates

20. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial Full Text available with Trip Pro

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalassemia (TDT)-induced osteoporosis are rather limited. Thus, we (...) conducted a randomized, placebo-controlled, double-blind, phase 2b clinical trial to evaluate DNM in TDT osteoporosis. Patients were assigned to receive either 60 mg DNM (n = 32) or placebo (n = 31) subcutaneously on day 0 and 180 during a total of 12 months of follow-up. The percentage increase of L1-L4 bone mineral density was higher in the DNM group than the placebo group (5.92% ± 5.25% vs 2.92% ± 5.56%, respectively; P = .043), whereas the advantage of DNM regarding wrist bone mineral density

2018 Blood advances Controlled trial quality: predicted high